Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer
BJU International · 2025
DOI: 10.1111/bju.16675 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, 2025. Verfasst von Pietro Scilipoti und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy, BCG Vaccine, Adjuvants, Immunologic. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess the oncological outcomes of patients with high‐risk (HR) and very high‐risk (VHR) non‐muscle‐invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette–Guérin (BCG) instillations from a contemporary European multicentre cohort. Patients and Methods We conducted a retrospective analysis of 1491 patients diagnosed with HR‐ or VHR‐NMIBC from a European multicentre database between 2015 and 2024. Patients were included if they received either upfront RC or at least five doses of BCG. A 1:1 propensity score matching (PSM) according to clinically relevant variables was applied. Progression was defined as muscle‐invasive or metastatic disease. Cumulative incidence plots and multivariable competing risk regression models addressing cancer‐specific mortality (CSM) were fitted.
Results
Among the 1221 patients with HR‐ ( n = 1221 [90%]) or VHR‐NMIBC ( n = 121 [10%]), 87 (7.1%) underwent upfront RC. The median follow‐up was 2.6 years. After PSM (87 vs 87 patients), the 5‐year CSM rate was similar in patients treated with BCG (13%) vs their upfront RC counterparts (16%) (hazard ratio: 1.77, 95% confidence interval [CI] 0.66–4.73; P = 0.3). Of the 1134 patients who initially received BCG, 73 (6.6%) eventually required delayed RC, with 34 (47%) progressing to muscle‐invasive bladder cancer before delayed RC. The 3‐year CSM rate was comparable in upfront RC (13%) vs delayed RC (11%) among non‐progressing patients ( P = 0.3). However, patients who progressed before delayed RC had worse 3‐year CSM relative to those who did not (13% vs 31%, hazard ratio: 0.32, 95% CI 0.13–0.83; P = 0.018).
Conclusion
Within a European cohort of patients with HR‐ and VHR‐NMIBC, upfront RC was rarely performed. Patients treated with BCG did not exhibit a CSM disadvantage relative to their upfront RC counterparts. After matching, long‐term CSM was similar between BCG therapy and upfront RC. Delayed RC, led to worse outcomes if performed after progression, but matched upfront RC when performed before progression, underscoring importance of timely surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
- Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France.
- Department of Urology and Oncologic Urology, Wrocław Medical University, Wroclaw, Poland.
ORCID-Profile: Pietro Scilipoti, Mario de Angelis, Aleksander Ślusarczyk, Francesco Soria, David D'Andrea, Andrea Mari, Francesco Del Giudice, Renate Pichler, José Daniel Subiela, Andrea Gallioli, Luca Afferi, Riccardo Mastroianni, Giuseppe Simone, Simone Albisinni, Laura S Mertens, Roberto Contieri, Keiichiro Mori, Francesco Montorsi, Andrea Salonia
Zitieren
APA
Scilipoti, P., Longoni, M., de Angelis, M., Zaurito, P., Ślusarczyk, A., Soria, F., Pradere, B., Krajewski, W., D'Andrea, D., Mari, A., Del Giudice, F., Pichler, R., Subiela, J. D., Marcq, G., Gallioli, A., Afferi, L., Mastroianni, R., Simone, G., Albisinni, S., …, & European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial carcinoma working group (2025). Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.16675
Vancouver
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Ślusarczyk A, Soria F, et al. Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer. BJU International. 2025. doi:10.1111/bju.16675
BibTeX
@article{Scilipoti2025,
author = {Scilipoti, Pietro and Longoni, Mattia and de Angelis, Mario and Zaurito, Paolo and Ślusarczyk, Aleksander and Soria, Francesco and Pradere, Benjamin and Krajewski, Wojciech and D'Andrea, David and Mari, Andrea and Del Giudice, Francesco and Pichler, Renate and Subiela, José Daniel and Marcq, Gautier and Gallioli, Andrea and Afferi, Luca and Mastroianni, Riccardo and Simone, Giuseppe and Albisinni, Simone and Mertens, Laura S and Laukhtina, Ekaterina and Oberneder, Katharina and Rodríguez Elena, José Luis and Aranda, Javier and Puentedura, Alfonso Lafuente and Caño Velasco, Jorge and Contieri, Roberto and Hurle, Rodolfo and Mori, Keiichiro and Radziszewski, Piotr and Shariat, Shahrokh F and Gontero, Paolo and Necchi, Andrea and Rouprêt, Morgan and Montorsi, Francesco and Salonia, Andrea and Briganti, Alberto and Moschini, Marco and European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial carcinoma working group, European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial carcinoma working group},
title = {Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16675}
}
EUVIMED